Active, not recruitingPhase 2NCT06422884

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Endeavor Biomedicines, Inc.
Principal Investigator: Lisa Lancaster, M.D.
Endeavor Biomedicines
Intervention: ENV-101(drug)
Enrollment: 213 target
Eligibility: 40 years · All sexes
Timeline: 2024 – 2026

Study locations (30)

Research Site, Quilmes, Buenos Aires, Argentina
Research Site, Buenos Aires, Argentina
Research Site, Mendoza, Argentina
Research Site, Camperdown, New South Wales, Australia
Research Site, Macquarie Park, New South Wales, Australia
Research Site, Brisbane, Queensland, Australia
Research Site, South Brisbane, Queensland, Australia
Research Site, Box Hill, Victoria, Australia
Research Site, Nedlands, Western Australia, Australia
Research Site, Graz, Styria, Austria
Research Site, Vienna, Austria
Research Site, Dinant, Namur, Belgium
Research Site, Brussels, Belgium
Research Site, Edmonton, Alberta, Canada
Research Site, Vancouver, British Columbia, Canada
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06422884 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials